{"preliminary_commentary":{"by_channel":{"youtube":2,"x_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["ruxolitinib","azacitidine"]],"indication":"myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasms","name":"NCT01787487","nct_id":"NCT01787487","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct01787487. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients with MF receive ruxolitinib phosphate PO BID on days 1-28. Beginning course 4, patients also receive azacytidine SC or IV for 5 days. Treatment repeats every 28 days for 15 courses in the absence of disease progression or unacceptable toxicity.","label":"Arm I (MF patients)","type":"EXPERIMENTAL"},{"description":"Patients with MDS/MPN receive ruxolitinib phosphate and azacytidine as in Arm I.","label":"Arm II (MDS/MPN patients)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2026-01-20","type":"ACTUAL"},"conditions":["Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable","Myelofibrosis Transformation in Essential Thrombocythemia","Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase","Primary Myelofibrosis"],"enrollment":{"count":121,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Azacitidine","otherNames":["5 AZC","5-AC","5-Azacytidine","5-AZC","Azacytidine","Azacytidine, 5-","Ladakamycin","Mylosar","U-18496","Vidaza"],"type":"DRUG"},{"name":"Laboratory Biomarker Analysis","otherNames":[],"type":"OTHER"},{"name":"Ruxolitinib Phosphate","otherNames":["INCB-18424 Phosphate","Jakafi"],"type":"DRUG"}],"last_update":"2026-03-31","lead_sponsor":"M.D. Anderson Cancer Center","official_title":"Evaluation of Ruxolitinib and Azacytidine Combination as a Therapy for Patients With Myelofibrosis and Myelodysplastic Syndrome/ Myeloproliferative Neoplasm","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2026-01-20","type":"ACTUAL"},"primary_outcomes":[{"measure":"Objective response rate (complete remission, partial remission, clinical improvement) in patients with myelofibrosis","timeFrame":"Up to 24 weeks"},{"measure":"Objective response rate (complete remission, partial remission, and hematologic improvement) in patients with myelodysplastic syndromes/myeloproliferative neoplasms","timeFrame":"Up to 24 weeks"}],"references":[{"citation":"Arora S, Senapati J, Deshmukh I, Bose P, Masarova L, Loghavi S, Wang X, Nogueras-Gonzalez G, Montalban-Bravo G, Borthakur G, DiNardo CD, Kadia T, Zhou L, Saenz D, Halim H, Alvarado Y, Ohanian M, Takahashi K, Short NJ, Jabbour E, Ravandi F, Garcia-Manero G, Pemmaraju N, Daver NG. Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasms. J Hematol Oncol. 2026 Jun 16. doi: 10.1186/s13045-026-01813-7. Online ahead of print.","pmid":"42304430","type":"DERIVED"},{"citation":"Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018 Oct 18;132(16):1664-1674. doi: 10.1182/blood-2018-04-846626. Epub 2018 Sep 5.","pmid":"30185431","type":"DERIVED"},{"citation":"Assi R, Kantarjian HM, Garcia-Manero G, Cortes JE, Pemmaraju N, Wang X, Nogueras-Gonzalez G, Jabbour E, Bose P, Kadia T, Dinardo CD, Patel K, Bueso-Ramos C, Zhou L, Pierce S, Gergis R, Tuttle C, Borthakur G, Estrov Z, Luthra R, Hidalgo-Lopez J, Verstovsek S, Daver N. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. Am J Hematol. 2018 Feb;93(2):277-285. doi: 10.1002/ajh.24972. Epub 2017 Nov 27.","pmid":"29134664","type":"DERIVED"}],"start_date":{"date":"2013-03-13","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm","url":"https://clinicaltrials.gov/study/NCT01787487"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct01787487"}